Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anita Viksna"'
Autor:
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett, Arnold G. Vulto
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of thi
Externí odkaz:
https://doaj.org/article/91efa0738a404ac58954a5cf23bc3c10
Autor:
Evelien Moorkens, Arnold G Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E Martikainen, Gisbert W Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon, Steven Simoens
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0190147 (2017)
Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.The aim of this article is to provide an overview of different initiatives and policies tha
Externí odkaz:
https://doaj.org/article/48cd055a3a8d489ebf5008a91ccd2ff9
Autor:
Vasileios Kourafalos, Eleonora Allocati, Luka Voncina, Brian Godman, Arianit Jakupi, Robert Plisko, Evelien Moorkens, Kateřina Kohoutová, Nataša Grubiša, Gisbert Selke, Anita Viksna, Arnold G. Vulto, Jurij Fürst, Jaana E. Martikainen, Leona Popelková, Ileana Mardare, Patricia Vella Bonanno, Vincent Suttorp, Dorthe Bartels, Sarah Mörtenhuber, Ott Laius, Iris Hoxha, Gustaf Befrits, Isabelle Huys, Dmitry Meshkov, Gnosia Achniotou, Rannveig Einarsdóttir, Øyvind Melien, Juraj Slabý, Ieva Greičiūtė-Kuprijanov, Simon Keuerleber, Einar Magnusson, Corinne Zara, Admir Malaj, Robert Puckett, Silvia Stockinger, Vanda Marković-Peković, Maria Dimitrova, Vera Vlahović Palčevski, Konstantin Tachkov, Tanja Novakovic, Roisin Adams, Roberta Joppi
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Frontiers in Pharmacology, 11:591134. Frontiers Media S.A.
Frontiers in Pharmacology
Volume 11
Frontiers in Pharmacology, 11:591134. Frontiers Media S.A.
Frontiers in Pharmacology
Volume 11
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of thi
Autor:
Evelien, Moorkens, Brian, Godman, Isabelle, Huys, Iris, Hoxha, Admir, Malaj, Simon, Keuerleber, Silvia, Stockinger, Sarah, Mörtenhuber, Maria, Dimitrova, Konstantin, Tachkov, Luka, Vončina, Vera Vlahović, Palčevski, Gnosia, Achniotou, Juraj, Slabý, Leona, Popelková, Kateřina, Kohoutová, Dorthe, Bartels, Ott, Laius, Jaana E, Martikainen, Gisbert W, Selke, Vasileios, Kourafalos, Einar, Magnússon, Rannveig, Einarsdóttir, Roisín, Adams, Roberta, Joppi, Eleonora, Allocati, Arianit, Jakupi, Anita, Viksna, Ieva, Greičiūtė-Kuprijanov, Patricia, Vella Bonanno, Vincent, Suttorp, Øyvind, Melien, Robert, Plisko, Ileana, Mardare, Dmitry, Meshkov, Tanja, Novakovic, Jurij, Fürst, Corinne, Zara, Vanda, Marković-Peković, Nataša, Grubiša, Gustaf, Befrits, Robert, Puckett, Arnold G, Vulto
Publikováno v:
Frontiers in Pharmacology
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry. Objectives: The aim of th
Autor:
Ljiljana Sović-Brkičić, Anita Viksna, Antra Fogele, Isabelle Huys, Einar Magnusson, Robin Šebesta, Asbjørn Mack, Laura McCullagh, Jaana E. Martikainen, Allan Karr, Susan Spillane, Morgane Beck, Juraj Slabý, Dmitry Meshkov, Simona Mencej Bedrač, Simon Keuerleber, Pieter Dylst, Patricia Vella Bonanno, Magdalena Władysiuk, Jurij Fürst, Steven Simoens, Brian Godman, Peter Skiold, Helder Mota-Filipe, Gisbert Selke, Gianluca Trifirò, Barbara Claus, Evelien Moorkens, Corrine Zara, Marija Kalaba, Arnold G. Vulto, Maria Dimitrova, Guenka Petrova, Ott Laius
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0190147 (2017)
PLoS ONE
PLOS ONE
PLoS One (online), 12(12):e0190147. Public Library of Science
PLoS ONE
PLOS ONE
PLoS One (online), 12(12):e0190147. Public Library of Science
Background: Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe. Objectives: The aim of this article is to provide an overview of different ini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5978f934421f021736ed4614f1e06dc8
https://strathprints.strath.ac.uk/62774/1/Moorkens_etal_PLOSone_2017_Policies_for_biosimilar_uptake_in_Europe.pdf
https://strathprints.strath.ac.uk/62774/1/Moorkens_etal_PLOSone_2017_Policies_for_biosimilar_uptake_in_Europe.pdf
Autor:
Stuart McTaggart, Kristina Garuoliene, Jurij Fürst, Scott M Bryson, Andrew Martin, Winne de Bruyn, Antra Fogele, Agnes Vitry, Hanne Bak Pedersen, Catherine Sermet, Gisbert Selke, Anne Marthe Ringerud, Krijn Schiffers, Eva Andersén Karlsson, Michael Wilcock, Anita Viksna, Irene Langner, Ljiljana Sović-Brkičić, Anna Coma Fusté, Marija Kalaba, Mikael Hoffmann, Peter Skiold, Sisira Jayathissa, Vanda Marković-Peković, Tomasz Bochenek, Einar Magnusson, Ott Laius, Christoph Baumgärtel, Scott Metcalfe, Corinne Zara, Brian Godman, D Tomek, Jutta Piessnegger, Rickard E. Malmström, Juraj Slabý, Harald Herholz, Jessica Fraeyman, Hye-Young Kwon, Marco D’Agata
Publikováno v:
Generics and Biosimilars Initiative Journal. 4:125-135
The manufacturer of pregabalin has a second use patent covering prescribing for neuropathic pain: its principal indication. The manufacturer has threatened legal action in the UK if generic pregabalin rather than Lyrica is prescribed for this indicat